Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2009

Open Access 01-12-2009 | Original investigation

Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study

Authors: Haruhiko Osawa, Yasufumi Doi, Hideichi Makino, Toshiharu Ninomiya, Koji Yonemoto, Ryoichi Kawamura, Jun Hata, Yumihiro Tanizaki, Mitsuo Iida, Yutaka Kiyohara

Published in: Cardiovascular Diabetology | Issue 1/2009

Login to get access

Abstract

Background

Resistin, secreted from adipocytes, causes insulin resistance in mice. The relationship between resistin and coronary artery disease is highly controversial, and the information regarding resistin and ischemic stroke is limited. In the present study, the association between serum resistin concentration and cardiovascular disease (CVD) was investigated in a general Japanese population.

Methods

A total of 3,201 community-dwelling individuals aged 40 years or older (1,382 men and 1,819 women) were divided into quintiles of serum resistin, and the association between resistin and CVD was examined cross-sectionally. The combined effect of either diabetes or hypertension and high serum resistin was also assessed. Serum resistin was measured using ELISA.

Results

Compared to those without CVD, age- and sex-adjusted mean serum resistin concentrations were greater in subjects with CVD (p = 0.002) or ischemic stroke (p < 0.001), especially in those with lacunar and atherothrombotic infarction, but not elevated in subjects with hemorrhagic stroke or coronary heart disease. When analyzed by quintile of serum resistin concentration, the age- and sex-adjusted odds ratio (OR) for having CVD and ischemic stroke increased with quintile of serum resistin (p for trends, 0.02 for CVD, < 0.001 for ischemic stroke), while such associations were not observed for hemorrhagic stroke or coronary heart disease. Compared to the first quintile, the age- and sex-adjusted OR of ischemic stroke was greater in the third (OR = 3.54; 95% confidence interval [CI], 1.17-10.67; p = 0.02), fourth (OR = 4.48; 95% CI, 1.53-13.09; p = 0.006), and fifth quintiles (OR = 4.70; 95% CI, 1.62-13.61; p = 0.004). These associations remained substantially unchanged even after adjustment for other confounding factors including high-sensitivity C-reactive protein. In the stratified analysis, the combination of high serum resistin and either diabetes or hypertension markedly increased the risk of ischemic stroke.

Conclusion

Elevated serum resistin concentration appears to be an independent risk factor for ischemic stroke, especially lacunar and atherothrombotic infarction in the general Japanese population. The combination of high resistin and the presence of either diabetes or hypertension increased the risk of ischemic stroke.
Appendix
Available only for authorised users
Literature
1.
go back to reference Steppan CM, Lazar MA: The current biology of resistin. J Intern Med. 2004, 255 (4): 439-447. 10.1111/j.1365-2796.2004.01306.x.CrossRefPubMed Steppan CM, Lazar MA: The current biology of resistin. J Intern Med. 2004, 255 (4): 439-447. 10.1111/j.1365-2796.2004.01306.x.CrossRefPubMed
2.
go back to reference Kim KH, Lee K, Moon YS, Sul HS: A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem. 2001, 276 (14): 11252-11256. 10.1074/jbc.C100028200.CrossRefPubMed Kim KH, Lee K, Moon YS, Sul HS: A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem. 2001, 276 (14): 11252-11256. 10.1074/jbc.C100028200.CrossRefPubMed
3.
go back to reference Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS: Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes. 2004, 53 (7): 1671-1679. 10.2337/diabetes.53.7.1671.CrossRefPubMed Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS: Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes. 2004, 53 (7): 1671-1679. 10.2337/diabetes.53.7.1671.CrossRefPubMed
4.
go back to reference Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature. 2001, 409 (6818): 307-312. 10.1038/35053000.CrossRefPubMed Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature. 2001, 409 (6818): 307-312. 10.1038/35053000.CrossRefPubMed
5.
go back to reference Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003, 300 (2): 472-476. 10.1016/S0006-291X(02)02841-3.CrossRefPubMed Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003, 300 (2): 472-476. 10.1016/S0006-291X(02)02841-3.CrossRefPubMed
6.
go back to reference Calabro P, Samudio I, Willerson JT, Yeh ET: Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004, 110 (21): 3335-3340. 10.1161/01.CIR.0000147825.97879.E7.CrossRefPubMed Calabro P, Samudio I, Willerson JT, Yeh ET: Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004, 110 (21): 3335-3340. 10.1161/01.CIR.0000147825.97879.E7.CrossRefPubMed
7.
go back to reference Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA: Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003, 108 (6): 736-740. 10.1161/01.CIR.0000084503.91330.49.CrossRefPubMed Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA: Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003, 108 (6): 736-740. 10.1161/01.CIR.0000084503.91330.49.CrossRefPubMed
8.
go back to reference Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, Pagano GF: Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond). 2005, 29 (11): 1315-1320. 10.1038/sj.ijo.0803037.CrossRef Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, Pagano GF: Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond). 2005, 29 (11): 1315-1320. 10.1038/sj.ijo.0803037.CrossRef
9.
go back to reference Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA: High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab. 2006, 91 (7): 2755-2760. 10.1210/jc.2005-2115.CrossRefPubMed Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA: High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab. 2006, 91 (7): 2755-2760. 10.1210/jc.2005-2115.CrossRefPubMed
10.
go back to reference Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004, 27 (10): 2450-2457. 10.2337/diacare.27.10.2450.CrossRefPubMed Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004, 27 (10): 2450-2457. 10.2337/diacare.27.10.2450.CrossRefPubMed
11.
go back to reference Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, Kim SY, Lee HK, Shimomura I, Park KS: Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis. 2008, 196 (1): 398-404. 10.1016/j.atherosclerosis.2006.11.017.CrossRefPubMed Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, Kim SY, Lee HK, Shimomura I, Park KS: Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis. 2008, 196 (1): 398-404. 10.1016/j.atherosclerosis.2006.11.017.CrossRefPubMed
12.
go back to reference Pilz S, Weihrauch G, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, Marz W: Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxf). 2007, 66 (3): 380-386. 10.1111/j.1365-2265.2007.02743.x.CrossRef Pilz S, Weihrauch G, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, Marz W: Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxf). 2007, 66 (3): 380-386. 10.1111/j.1365-2265.2007.02743.x.CrossRef
13.
go back to reference Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005, 111 (7): 932-939. 10.1161/01.CIR.0000155620.10387.43.CrossRefPubMed Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005, 111 (7): 932-939. 10.1161/01.CIR.0000155620.10387.43.CrossRefPubMed
14.
go back to reference Weikert C, Westphal S, Berger K, Dierkes J, Mohlig M, Spranger J, Rimm EB, Willich SN, Boeing H, Pischon T: Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab. 2008, 93 (7): 2647-2653. 10.1210/jc.2007-2735.CrossRefPubMed Weikert C, Westphal S, Berger K, Dierkes J, Mohlig M, Spranger J, Rimm EB, Willich SN, Boeing H, Pischon T: Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab. 2008, 93 (7): 2647-2653. 10.1210/jc.2007-2735.CrossRefPubMed
15.
go back to reference Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Arima H, Hata J, Tanizaki Y, Iida M, Kiyohara Y: Fasting plasma glucose cutoff for diagnosis of diabetes in a Japanese population. J Clin Endocrinol Metab. 2008, 93 (9): 3425-3429. 10.1210/jc.2007-2819.CrossRefPubMed Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Arima H, Hata J, Tanizaki Y, Iida M, Kiyohara Y: Fasting plasma glucose cutoff for diagnosis of diabetes in a Japanese population. J Clin Endocrinol Metab. 2008, 93 (9): 3425-3429. 10.1210/jc.2007-2819.CrossRefPubMed
16.
go back to reference Kubo M, Kiyohara Y, Ninomiya T, Tanizaki Y, Yonemoto K, Doi Y, Hata J, Oishi Y, Shikata K, Iida M: Decreasing incidence of lacunar vs other types of cerebral infarction in a Japanese population. Neurology. 2006, 66 (10): 1539-1544. 10.1212/01.wnl.0000216132.95207.b4.CrossRefPubMed Kubo M, Kiyohara Y, Ninomiya T, Tanizaki Y, Yonemoto K, Doi Y, Hata J, Oishi Y, Shikata K, Iida M: Decreasing incidence of lacunar vs other types of cerebral infarction in a Japanese population. Neurology. 2006, 66 (10): 1539-1544. 10.1212/01.wnl.0000216132.95207.b4.CrossRefPubMed
17.
go back to reference Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama Study. Stroke. 2003, 34 (10): 2349-2354. 10.1161/01.STR.0000090348.52943.A2.CrossRefPubMed Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama Study. Stroke. 2003, 34 (10): 2349-2354. 10.1161/01.STR.0000090348.52943.A2.CrossRefPubMed
18.
go back to reference A report by a committee established by the Director of the National Institute of Neurological Disorders and Stroke NIoH, Bethesda, Maryland: Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke. 1990, 21 (4): 637-676.CrossRef A report by a committee established by the Director of the National Institute of Neurological Disorders and Stroke NIoH, Bethesda, Maryland: Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke. 1990, 21 (4): 637-676.CrossRef
19.
go back to reference Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993, 24 (1): 35-41.CrossRefPubMed Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993, 24 (1): 35-41.CrossRefPubMed
20.
go back to reference Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol. 1986, 43 (1): 71-84. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol. 1986, 43 (1): 71-84.
21.
go back to reference Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, Fujishima M: Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke. 2000, 31 (11): 2616-2622.CrossRefPubMed Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, Arima H, Tanaka K, Ibayashi S, Fujishima M: Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke. 2000, 31 (11): 2616-2622.CrossRefPubMed
22.
go back to reference Osawa H, Onuma H, Ochi M, Murakami A, Yamauchi J, Takasuka T, Tanabe F, Shimizu I, Kato K, Nishida W: Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun. 2005, 335 (2): 596-602.CrossRefPubMed Osawa H, Onuma H, Ochi M, Murakami A, Yamauchi J, Takasuka T, Tanabe F, Shimizu I, Kato K, Nishida W: Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun. 2005, 335 (2): 596-602.CrossRefPubMed
23.
go back to reference Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, Nishida W, Yamada K, Nakura J, Kohara K: Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care. 2007, 30 (6): 1501-1506. 10.2337/dc06-1936.CrossRefPubMed Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H, Nishida W, Yamada K, Nakura J, Kohara K: Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care. 2007, 30 (6): 1501-1506. 10.2337/dc06-1936.CrossRefPubMed
24.
go back to reference Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, Nishimiya T, Niiya T, Shimizu I, Nishida W: The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 2004, 75 (4): 678-686. 10.1086/424761.PubMedCentralCrossRefPubMed Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, Nishimiya T, Niiya T, Shimizu I, Nishida W: The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 2004, 75 (4): 678-686. 10.1086/424761.PubMedCentralCrossRefPubMed
26.
go back to reference Tsukahara T, Nakashima E, Watarai A, Hamada Y, Naruse K, Kamiya H, Nakamura N, Kato N, Hamajima N, Sekido Y: Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2009, 84 (2): 179-186. 10.1016/j.diabres.2008.10.021.CrossRefPubMed Tsukahara T, Nakashima E, Watarai A, Hamada Y, Naruse K, Kamiya H, Nakamura N, Kato N, Hamajima N, Sekido Y: Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2009, 84 (2): 179-186. 10.1016/j.diabres.2008.10.021.CrossRefPubMed
27.
go back to reference Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU: Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001, 32 (12): 2735-2740. 10.1161/hs1201.100209.CrossRefPubMed Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU: Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001, 32 (12): 2735-2740. 10.1161/hs1201.100209.CrossRefPubMed
28.
go back to reference Saposnik G, Caplan LR, Gonzalez LA, Baird A, Dashe J, Luraschi A, Llinas R, Lepera S, Linfante I, Chaves C: Differences in stroke subtypes among natives and caucasians in Boston and Buenos Aires. Stroke. 2000, 31 (10): 2385-2389.CrossRefPubMed Saposnik G, Caplan LR, Gonzalez LA, Baird A, Dashe J, Luraschi A, Llinas R, Lepera S, Linfante I, Chaves C: Differences in stroke subtypes among natives and caucasians in Boston and Buenos Aires. Stroke. 2000, 31 (10): 2385-2389.CrossRefPubMed
29.
go back to reference Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A: Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005, 174 (9): 5789-5795.CrossRefPubMed Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A: Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005, 174 (9): 5789-5795.CrossRefPubMed
30.
go back to reference Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I: Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism. 2008, 57 (4): 494-501. 10.1016/j.metabol.2007.11.010.CrossRefPubMed Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I: Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism. 2008, 57 (4): 494-501. 10.1016/j.metabol.2007.11.010.CrossRefPubMed
31.
go back to reference Kunnari A, Ukkola O, Kesaniemi YA: Resistin polymorphisms are associated with cerebrovascular disease in Finnish Type 2 diabetic patients. Diabet Med. 2005, 22 (5): 583-589. 10.1111/j.1464-5491.2005.01480.x.CrossRefPubMed Kunnari A, Ukkola O, Kesaniemi YA: Resistin polymorphisms are associated with cerebrovascular disease in Finnish Type 2 diabetic patients. Diabet Med. 2005, 22 (5): 583-589. 10.1111/j.1464-5491.2005.01480.x.CrossRefPubMed
Metadata
Title
Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: the Hisayama Study
Authors
Haruhiko Osawa
Yasufumi Doi
Hideichi Makino
Toshiharu Ninomiya
Koji Yonemoto
Ryoichi Kawamura
Jun Hata
Yumihiro Tanizaki
Mitsuo Iida
Yutaka Kiyohara
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2009
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-8-60

Other articles of this Issue 1/2009

Cardiovascular Diabetology 1/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.